JSPR Jul 2024 25.000 call
| Previous close | 2.6200 |
| Open | 2.6300 |
| Bid | 1.9000 |
| Ask | 4.4000 |
| Strike | 25.00 |
| Expiry date | 2024-07-19 |
| Day's range | 2.6300 - 2.6300 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
GlobeNewswireJasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter ended March 31, 2024, and reported recent corporate developments. “We have continued to make stron
- GlobeNewswire
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4 2024Company to Host Key Opinion Leader Webinar on the Potential of Briquilimab in Asthma on May 20, 2024, at 8:00 a.m. EDT REDWOOD CITY, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven d
- GlobeNewswire
Jasper Therapeutics to Present at Upcoming Investor Conferences in May
REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the following upcoming investor conferences in May: Capital One Securities Biotech/Biopharma Disruptors Even
